Literature DB >> 26370423

Non-coding RNAs deregulation in oral squamous cell carcinoma: advances and challenges.

T Yu1, C Li2, Z Wang2, K Liu2, C Xu2, Q Yang2, Y Tang2, Y Wu3.   

Abstract

Oral squamous cell carcinoma (OSCC) is a common cause of cancer death. Despite decades of improvements in exploring new treatments and considerable advance in multimodality treatment, satisfactory curative rates have not yet been reached. The difficulty of early diagnosis and the high prevalence of metastasis associated with OSCC contribute to its dismal prognosis. In the last few decades the emerging data from both tumor biology and clinical trials led to growing interest in the research for predictive biomarkers. Non-coding RNAs (ncRNAs) are promising biomarkers. Among numerous kinds of ncRNAs, short ncRNAs, such as microRNAs (miRNAs), have been extensively investigated with regard to their biogenesis, function, and importance in carcinogenesis. In contrast to miRNAs, long non-coding RNAs (lncRNAs) are much less known concerning their functions in human cancers especially in OSCC. The present review highlighted the roles of miRNAs and newly discovered lncRNAs in oral tumorigenesis, metastasis, and their clinical implication.

Entities:  

Keywords:  Long non-coding RNAs; Non-coding RNAs; Oral squamous cell carcinoma; microRNAs

Mesh:

Substances:

Year:  2015        PMID: 26370423     DOI: 10.1007/s12094-015-1404-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  86 in total

Review 1.  Long noncoding RNAs in cell biology.

Authors:  Michael B Clark; John S Mattick
Journal:  Semin Cell Dev Biol       Date:  2011-01-20       Impact factor: 7.727

Review 2.  Epigenetic mechanisms in oral carcinogenesis.

Authors:  Jacqueline A Gasche; Ajay Goel
Journal:  Future Oncol       Date:  2012-11       Impact factor: 3.404

3.  Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival.

Authors:  Tom Donnem; Kenneth Lonvik; Katrine Eklo; Thomas Berg; Sveinung W Sorbye; Khalid Al-Shibli; Samer Al-Saad; Sigve Andersen; Helge Stenvold; Roy M Bremnes; Lill-Tove Busund
Journal:  Cancer       Date:  2011-01-24       Impact factor: 6.860

4.  Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.

Authors:  Meritxell Gironella; Mylène Seux; Min-Jue Xie; Carla Cano; Richard Tomasini; Julien Gommeaux; Stephane Garcia; Jonathan Nowak; Man Lung Yeung; Kuan-Teh Jeang; Amandine Chaix; Ladan Fazli; Yoshiharu Motoo; Qing Wang; Palma Rocchi; Antonio Russo; Martin Gleave; Jean-Charles Dagorn; Juan L Iovanna; Alice Carrier; Marie-Josèphe Pébusque; Nelson J Dusetti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

Review 5.  State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013.

Authors:  Nerina Denaro; Elvio Grazioso Russi; Vincenzo Adamo; Marco Carlo Merlano
Journal:  Oncology       Date:  2014-05-10       Impact factor: 2.935

6.  Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer.

Authors:  Qin Xu; Qiang Sun; Jianjun Zhang; Jingshuang Yu; Wantao Chen; Zhiyuan Zhang
Journal:  Carcinogenesis       Date:  2012-11-27       Impact factor: 4.944

7.  The transcriptional landscape of the mammalian genome.

Authors:  P Carninci; T Kasukawa; S Katayama; J Gough; M C Frith; N Maeda; R Oyama; T Ravasi; B Lenhard; C Wells; R Kodzius; K Shimokawa; V B Bajic; S E Brenner; S Batalov; A R R Forrest; M Zavolan; M J Davis; L G Wilming; V Aidinis; J E Allen; A Ambesi-Impiombato; R Apweiler; R N Aturaliya; T L Bailey; M Bansal; L Baxter; K W Beisel; T Bersano; H Bono; A M Chalk; K P Chiu; V Choudhary; A Christoffels; D R Clutterbuck; M L Crowe; E Dalla; B P Dalrymple; B de Bono; G Della Gatta; D di Bernardo; T Down; P Engstrom; M Fagiolini; G Faulkner; C F Fletcher; T Fukushima; M Furuno; S Futaki; M Gariboldi; P Georgii-Hemming; T R Gingeras; T Gojobori; R E Green; S Gustincich; M Harbers; Y Hayashi; T K Hensch; N Hirokawa; D Hill; L Huminiecki; M Iacono; K Ikeo; A Iwama; T Ishikawa; M Jakt; A Kanapin; M Katoh; Y Kawasawa; J Kelso; H Kitamura; H Kitano; G Kollias; S P T Krishnan; A Kruger; S K Kummerfeld; I V Kurochkin; L F Lareau; D Lazarevic; L Lipovich; J Liu; S Liuni; S McWilliam; M Madan Babu; M Madera; L Marchionni; H Matsuda; S Matsuzawa; H Miki; F Mignone; S Miyake; K Morris; S Mottagui-Tabar; N Mulder; N Nakano; H Nakauchi; P Ng; R Nilsson; S Nishiguchi; S Nishikawa; F Nori; O Ohara; Y Okazaki; V Orlando; K C Pang; W J Pavan; G Pavesi; G Pesole; N Petrovsky; S Piazza; J Reed; J F Reid; B Z Ring; M Ringwald; B Rost; Y Ruan; S L Salzberg; A Sandelin; C Schneider; C Schönbach; K Sekiguchi; C A M Semple; S Seno; L Sessa; Y Sheng; Y Shibata; H Shimada; K Shimada; D Silva; B Sinclair; S Sperling; E Stupka; K Sugiura; R Sultana; Y Takenaka; K Taki; K Tammoja; S L Tan; S Tang; M S Taylor; J Tegner; S A Teichmann; H R Ueda; E van Nimwegen; R Verardo; C L Wei; K Yagi; H Yamanishi; E Zabarovsky; S Zhu; A Zimmer; W Hide; C Bult; S M Grimmond; R D Teasdale; E T Liu; V Brusic; J Quackenbush; C Wahlestedt; J S Mattick; D A Hume; C Kai; D Sasaki; Y Tomaru; S Fukuda; M Kanamori-Katayama; M Suzuki; J Aoki; T Arakawa; J Iida; K Imamura; M Itoh; T Kato; H Kawaji; N Kawagashira; T Kawashima; M Kojima; S Kondo; H Konno; K Nakano; N Ninomiya; T Nishio; M Okada; C Plessy; K Shibata; T Shiraki; S Suzuki; M Tagami; K Waki; A Watahiki; Y Okamura-Oho; H Suzuki; J Kawai; Y Hayashizaki
Journal:  Science       Date:  2005-09-02       Impact factor: 47.728

8.  Methylation-mediated molecular dysregulation in clinical oral malignancy.

Authors:  Rebecca Towle; Cathie Garnis
Journal:  J Oncol       Date:  2012-05-07       Impact factor: 4.375

9.  High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma.

Authors:  Carla Hebert; Kathleen Norris; Mark A Scheper; Nikolaos Nikitakis; John J Sauk
Journal:  Mol Cancer       Date:  2007-01-14       Impact factor: 27.401

10.  Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma.

Authors:  Min Zheng; Ya-ping Jiang; Wei Chen; Kai-de Li; Xin Liu; Shi-yu Gao; Hao Feng; Sha-sha Wang; Jian Jiang; Xiang-rui Ma; Xiao Cen; Ya-jie Tang; Yu Chen; Yun-feng Lin; Ya-ling Tang; Xin-hua Liang
Journal:  Oncotarget       Date:  2015-03-30
View more
  5 in total

1.  Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/β-catenin signaling pathway.

Authors:  Guang-Hui Li; Zhong-Hui Ma; Xi Wang
Journal:  Cell Cycle       Date:  2019-09-04       Impact factor: 4.534

2.  MicroRNA-196a-5p is a potential prognostic marker of delayed lymph node metastasis in early-stage tongue squamous cell carcinoma.

Authors:  Tessho Maruyama; Kazuhide Nishihara; Masato Umikawa; Akira Arasaki; Toshiyuki Nakasone; Fumikazu Nimura; Akira Matayoshi; Kimiko Takei; Saori Nakachi; Ken-Ichi Kariya; Naoki Yoshimi
Journal:  Oncol Lett       Date:  2017-12-08       Impact factor: 2.967

3.  LINC00152 promotes the growth and invasion of oral squamous cell carcinoma by regulating miR-139-5p.

Authors:  Minghe Li; Jun Ning; Zhihong Li; Jing Wang; Cong Zhao; Lei Wang
Journal:  Onco Targets Ther       Date:  2018-09-27       Impact factor: 4.147

Review 4.  Long non-coding RNAs in Oral squamous cell carcinoma: biologic function, mechanisms and clinical implications.

Authors:  Lei Zhang; Xiang Meng; Xin-Wei Zhu; Deng-Cheng Yang; Ran Chen; Yong Jiang; Tao Xu
Journal:  Mol Cancer       Date:  2019-05-27       Impact factor: 27.401

5.  Suppression of the long non-coding RNA MALAT-1 impairs the growth and migration of human tongue squamous cell carcinoma SCC4 cells.

Authors:  Xu Han; Zixiao Xu; Gang Tian; Zhen Tang; JianYong Gao; Yibo Wei; XiaoGang Xu
Journal:  Arch Med Sci       Date:  2018-03-02       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.